Igrene (ABI) Q2 2025 earnings summary

Executive summary

• Operating loss for the period was -5,030 KSEK compared to -1,339 KSEK in the same period last year.

• Net result after financial items was -5,029 KSEK, with earnings per share at -0.05 SEK (-0.02 SEK last year).

• Strategic focus remains on extracting hydrogen and carbon from biogenic methane using a CO2-free process in partnership with SEID AS.

• The company is pursuing a demonstration plant for hydrogen and carbon production, supported by EU funding and recognized for innovation.

Financial highlights

• Revenue for the period was 0 KSEK, down from 155 KSEK in the same period last year.

• Total costs increased to 4,957 KSEK from 1,417 KSEK year-over-year.

• Cash and cash equivalents at period end were 8,381 KSEK, up from 3,047 KSEK a year earlier.

• Equity ratio improved to 95.0% from 83.9% year-over-year.

• Short-term liabilities totaled 1,394 KSEK at period end.

Outlook and guidance

• The company aims to commercialize its methane-to-hydrogen and carbon technology, with plans for global expansion leveraging modularity and European gas infrastructure.

• Hydrogen and carbon are positioned as key products for the green transition, with significant market potential.